secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeoVax Labs, Inc. (GOVX)
CIK:        0000832489
Form:       8-K
Filed at:   2026-07-27T20:33:24+00:00
Accession:  0001437749-26-024522
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeoVax Q2 net loss $4.4M ($0.97/share); advancing GEO-MVA pivotal study planned Q4 2026
--------------------------------------------------------------------------------

- Net loss for Q2 2026 was $4.4M ($0.97 per share) vs $5.4M ($8.74 per share) in Q2 2025.
- No revenue in Q2 2026 after BARDA contract termination; Q2 2025 had $852K government contract revenue.
- Cash $3.1M at June 30, 2026, unchanged from Dec 31, 2025.
- Discontinued GEO-CM04S1 COVID-19 vaccine development due to market contraction; no safety concerns.
- Planning to initiate pivotal GEO-MVA immunobridging study in Q4 2026 under EMA expedited pathway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/832489/000143774926024522/0001437749-26-024522-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/832489/000143774926024522/govx20260727_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-024522

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer